DOCSLIB.ORG

Table 3.0: Diagnostic Categories and ICD-9-CM & ICD-10-CM Codes For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 3.0: Diagnostic Categories and ICD-9-CM & ICD-10-CM Codes For Table 3.0: Diagnostic Categories and ICD-9-CM & ICD-10-CM Codes for Arthritis and Other Rheumatic Conditions (AORC) ICD-9-CM ICD-10-CM Osteoarthritis and allied disorders Osteoarthritis and allied disorders 715 Osteoarthritis and allied disorders M15.x Polyosteoarthritis M16.x Osteoarthrisis of hip M17.x Osteoarthritis of knee M18.x Osteoarthritis of first carpometacarpal joint M19.x Other and unspecified osteoarthritis Rheumatoid arthritis Inflammatory polyarthropathies 714 Rheumatoid arthritis and other inflammatory polyarthropathies M05.x Rheumatoid arthritis with rheumatoid factor M06.x Other rheumatoid arthropathies M07.x Enteropathic arthropathies M08.x Juvenile arthritis M12.0x Chronic postrheumatic arthropathy [Jaccoud] Gout and other crystal arthropathies Gout and other crystal arthropathies 274 Gout M1A.x Chronic gout 712 Crystal arthropathies M10.x Gout M11.x Other crystal arthropathies Joint pain/effusion/other unspecified joint disorders Joint pain, effusion and other unspecified joint disorders 716.1, .3-.6.9 Other unspecified arthropathies M12.5x Traumatic arthropathy 719.0, .4-.9 Other and unspecified joint disorders M13.8x Other specified arthritis M13.1x Monarthritis, not elsewhere classified M12.9 Arthropathy, unspecified M25.4x Effusion of joint M25.5x Pain in joint M25.9 Joint disorder, unspecified Spondyloarthropathies Spondylarthropathies 720 AS/inflammatory spondylopathies M45.x Ankylosing spondylitis M46.0x Spinal enthesopathy, site unspecified M46.1 Sacroiliitis, not elsewhere classified M49.80 Spondylopathy in diseases classified elsewhere, site unspecified M46.8 Other specified inflammatory spondylopathies, site unspecified M46.9 Unspecified inflammatory spondylopathy, site unspecified 721 Spondylosis and allied disorders M46x Other inflammatory spondylopathies M47.12 Other spondylosis with myelopathy, cervical region M47.8x Other spondylosis M47.1x Other spondylosis with myelopathy M47.2x Other spondylosis with radiculopathy M48.2x Kissing spine M48.1x Ankylosing hyperostosis [Forestier] M48.3x Traumatic spondylopathy M48.9 Spondylopathy, unspecified 99.3 Reiter’s Disease M02.3x Reiter's disease 696 Psoriatic arthopathy L40.5x Arthropathic psoriasis 1 Table 3.0: Diagnostic Categories and ICD-9-CM & ICD-10-CM Codes for Arthritis and Other Rheumatic Conditions (AORC) ICD-9-CM ICD-10-CM Fibromyalgia Fibromyalgia 729.1 Myalgia and myositis unspecified M60.9 Myositis M79.1 Myalgia M70.9 Fibromyalgia Diffuse connective tissue disease Systemic connective tissue disorders 710 Systemic lupus erythematosus (SLE) M32.10 Systemic lupus erythematosus, organ or system involvement unspecified M32.19 Other organ or system involvement in systemic lupus erythematosus M32.8 Other forms of systemic lupus erythematosus M32.9 Systemic lupus erythematosus, unspecified 710.1 Systemic sclerosis (SSC, scleroderma) M34.0 Progressive systemic scleros M34.1 CR(E)ST syndrome M34.9 Systemic sclerosis, unspecified 710.2 Sicca syndrome (also called Sjögren's syndrome) M35.00 Sicca syndrome, unspecified M35.01 Sicca syndrome with keratoconjunctivitis 710.3 Dermatomyositis M33.90 Dermatopolymyositis, unspecified, organ involvement unspecified 710.4 Polymyositis M33.20 Polymyositis, organ involvement unspecified 710.5 Eosinophilia myalgia syndrome M35.8 Other specified systemic involvement of connective tissue 710.8 Other specified diffuse diseases of connective tissue M35.5 Multifocal fibrosclerosis 710.9 Unspecified diffuse connective tissue disease M35.9 Systemic involvement of connective tissue, unspecified Carpal tunnel syndrome Carpal tunnel syndrome 354 Carpal tunnel syndrome G56.0 Carpal tunnel syndrome Soft tissue disorders (excluding back) Soft tissue disorders (excluding back) 726 Peripheral enthesopathies and allied disorders M75.00 Adhesive capsulitis of unspecified shoulder M75.100 Unspecified rotator cuff tear or rupture of unspecified shoulder, not specified as traumatic M75.50 Bursitis of unspecified shoulder M75.30 Calcific tendinitis of unspecified shoulder M75.20 Bicipital tendinitis, unspecified shoulder M75.110 Incomplete rotator cuff tear or rupture of unspecified shoulder, not specified as traumatic M75.80 Other shoulder lesions, unspecified shoulder M75.40 Impingement syndrome of unspecified should M25.729 Osteophyte, unspecified elbow M77.00 Medial epicondylitis, unspecified elbow M77.10 Lateral epicondylitis, unspecified elbow M70.20 Olecranon bursitis, unspecified elbow M70.30 Other bursitis of elbow, unspecified elbow M77.20 Periarthritis, unspecified wrist M70.60 Trochanteric bursitis, unspecified hip M70.70 Other bursitis of hip, unspecified hip M76.10 Psoas tendinitis, unspecified hip M76.20 Iliac crest spur, unspecified hip M70.50 Other bursitis of knee, unspecified knee M76.899 Other specified enthesopathies of unspecified lower limb, excluding foot M76.40 Tibial collateral bursitis [Pellegrini-Stieda], unspecified leg M76.50 Patellar tendinitis, unspecified knee M70.50 Prepatellar bursitis, unspecified knee M77.40 Metatarsalgia, unspecified foot 2 Table 3.0: Diagnostic Categories and ICD-9-CM & ICD-10-CM Codes for Arthritis and Other Rheumatic Conditions (AORC) ICD-9-CM ICD-10-CM M76.60 Achilles tendinitis, unspecified leg M76.829 Posterior tibial tendinitis, unspecified leg M77.30 Calcaneal spur, unspecified foot M77.50 Other enthesopathy of unspecified foot M77.8 Other enthesopathies, not elsewhere classified M77.9 Enthesopathy, unspecified M25.70 Osteophyte, unspecified joint 727 Other disorders of synovium/tendon/bursa M65.9 Synovitis and tenosynovitis, unspecified 728.0-.3, .6–.9 Disorders of muscle/ligament/fascia 728.0 M60.009 Infective myositis, unspecified site 728.1 M61.9x Calcification and ossification of muscle 728.2 M62.5x Muscle wasting and atrophy, not elsewhere classified 728.3 M62.3 Immobility syndrome (paraplegic) M62.84 Sarcopenia M62.89 Other specified disorders of muscle 728.6 M72.0 Palmar fascial fibromatosis [Dupuytren] 728.7 M72.2 Plantar fascial fibromatosis 728.8 M60.1 Interstitial myositis of unspecified site 728.9 M62.9 Disorder of muscle, unspecified 729 Rheumatism, unspecified and fibrositis M79.0 Rheumatism, unspecified 729.4 Fascitis, unspecified M72.9 Fibroblastic disorder, unspecified Other specified rheumatic conditions Other specified rheumatic conditions 95.6 Syphilis of muscle A52.78 Syphilis of other musculoskeletal tissue 95.7 Syphilis of synovium/tendon/bursa " " " " 98.5 Gonococcal infection of joint A54.42 Gonoccal arthritis 136.1 Behcet’s syndrome M35.2 Behcet's disease 277.2 Other disorders purine/pyrimidine metabolism E79.1 Lesch-Nyhan syndrome E79.8 Other disorders purine and pyrimidine metabolism 287 Allergic purpura D69.0 Allergic purpura 344.6 Cauda equina syndrome G83.4 Cauda equina syndrome 353 Brachial plexus/thoracic outlet lesions G54.0 Brachial plexus disorders 355.5 Tarsal tunnel syndrome G57.50 Tarsal tunnel syndrome, unspecified lower limb 357.1 Polyneuropathy in collagen vascular disease G63 Polyneuropathy in diseases classified elsewher 390 Rheumatic fever w/o heart disease I00 Rheumatic fever without heart involvement 391 Rheumatic fever w/heart disease I01.0 Acute rheumatic pericarditis I01.2 Acute rheumatic myocarditi I01.8 Other acute rheumatic heart disease I01.9 Acute rheumatic heart disease, unspecified 437.4 Cerebral arteritis I67.6 Cerebral arteritis, not elsewhere classified 443 Raynaud’s syndrome I73.00 Raynaud's syndrome without gangrene 446 Polyarteritis nodosa and allied conditions [excl 446.5] M30.0 Polyarteritis nodos M30.3 Mucocutaneous lymph node syndrome [Kawasaki] M31.0 Hypersensitivity angiitis M31.2 Lethal midline granuloma M31.3 Wegener's granulomatosis without renal involvement M31.1 Thrombotic microangiopath M31.4 Aortic arch syndrome [Takayasu] 3 447.6 Arteritis, unspecified I77.6 Arteritis, unspecified Table 3.0: Diagnostic Categories and ICD-9-CM & ICD-10-CM Codes for Arthritis and Other Rheumatic Conditions (AORC) ICD-9-CM ICD-10-CM 711 Arthritis associated with infections M00.x Pyogenic arthritis M02.3x Reiter's disease M35.2 Behçet's disease M02.1x Postdysenteric arthropathy M01.Xx Direct joint infections and parasitic diseases 713 Arthropathy associated w/disorders classified elsewhere M14.80 Arthropathies in other specified diseases classified elsewhere, unspecified site M02.00 Arthropathy following intestinal bypass, unspecified site M36.2 Hemophilic arthropathy M36.3 Arthropathy in other blood disorders M12.8 Other specific arthropathies, not elsewhere classified, unspecified site M14.60 Charcôt's joint, unspecified sit M02.20 Postimmunization arthropathy, unspecified site M36.4 Arthropathy in hypersensitivity reactions classified elsewhere M02.9 Reactive arthropathy, unspecified 716.0, .2, .8 Specified arthropathies M12.1x Kaschin-Beck disease M13.8x Other specified arthritis M12.8x Other specific arthropathies, not elsewhere classified 719.2, .3 Specified joint disorders M12.2x Villonodular synovitis (pigmented) M12.3x Palindromic rheumatism M12.4x Intermittent hydrarthrosis 725 Polymyalgia rheumatica M35.3 Polymyalgia rheumatica Source: "National Arthritis Data Workgroup ICD-9-CM diagnostic codes for arthritis and other rheumatic conditions." Centers for Disease Control and Prevention, Arthritis Program, National Arthritis Data Workgroup. http://www.cdc.gov/arthritis/data_statistics/arthritis_codes_2004.pdf (October 29, 2013) 4.
Load more

Recommended publications
  • 18-0969: R.S. and DEPARTMENT of the ARMY, WALTER
    United States Department of Labor Employees’ Compensation Appeals Board __________________________________________ ) R.S., Appellant ) ) and ) Docket No. 18-0969 ) Issued: March 27, 2019 DEPARTMENT OF THE ARMY, WALTER ) REED NATIONAL MILITARY MEDICAL ) CENTER, Bethesda, MD, Employer ) _________________________________________ ) Appearances: Case Submitted on the Record Appellant, pro se Office of Solicitor, for the Director DECISION AND ORDER Before: CHRISTOPHER J. GODFREY, Chief Judge PATRICIA H. FITZGERALD, Deputy Chief Judge VALERIE D. EVANS-HARRELL, Alternate Judge JURISDICTION On April 10, 2018 appellant filed a timely appeal from a December 22, 2017 merit decision of the Office of Workers’ Compensation Programs (OWCP). Pursuant to the Federal Employees’ Compensation Act1 (FECA) and 20 C.F.R. §§ 501.2(c) and 501.3, the Board has jurisdiction over the merits of this case.2 ISSUE The issue is whether appellant has met her burden of proof to establish lumbar and/or right shoulder conditions causally related to an April 7, 2016 employment incident. 1 5 U.S.C. § 8101 et seq. 2 The Board notes that following the December 22, 2017 decision, OWCP received additional evidence. However, the Board’s Rules of Procedure provides: “The Board’s review of a case is limited to the evidence in the case record that was before OWCP at the time of its final decision. Evidence not before OWCP will not be considered by the Board for the first time on appeal.” 20 C.F.R. § 501.2(c)(1). Thus, the Board is precluded from reviewing this additional evidence for the first time on appeal. Id. FACTUAL HISTORY On April 15, 2016 appellant, then a 64-year-old radiology technology supervisor, filed a traumatic injury claim (Form CA-1) alleging that on April 7, 2016 she injured her lower back and right shoulder while in the performance of duty.
    [Show full text]
  • Tuberculous Spondylitis, Pyogenic Spondylitis, X-Ray and Tomographic Features
    American Journal of Medicine and Medical Sciences 2021, 11(5): 398-401 DOI: 10.5923/j.ajmms.20211105.08 X-Ray and Tomographic Manifestations of Tuberculous Spondylitis Babоev Abduvakhob Sakhibnazarovich Bone and Joint Tuberculosis Department of Rebuplican Specialized Scientific Practical Medical Center of Phtiziology and Pulmonology, Tashkent, Uzbekistan Abstract X-ray and tomographic data of seventy-eight patients with spine disorders (31 patients with tuberculous spondylitis, 23 patients with pyogenic spondylitis, and 24 patients with degenerative spondylopathy) after clinical, laboratory, bacteriologic, and histologic verification of diagnosis was comparatively analyzed. Current X-ray and tomographic features of tuberculous spondylitis are relatively equal thoracic and lumbosacral spine segments localization, with more than two adjacent vertebrae involvement in 22,6±7,5% of cases, the collapse of the vertebra(s) in 35.5 ± 8.6% of cases, unclear or osteoporotic border of bone tissue around TB focus in 64.5 ± 8.6%, formation of abscesses in 74.2±7.9% and their subligamentous spread to more than two vertebrae in 25,8±7,9% of cases, intact intervertebral disc in 16.1 ± 6.6% of cases, and specific process in the lungs in 48.4 ± 9.0% of cases. Keywords Tuberculous spondylitis, Pyogenic spondylitis, X-ray and tomographic features identify differential diagnostic features of tuberculous 1. Introduction spondylitis (TS). X-ray and tomographic (MRI and CT) methods of examination play a leading role in the diagnosis of 3. Materials and Methods tuberculous (TB) lesions of the spine [1,2,3]. Features of radiological changes of spine TB depend on The study was conducted at the bone and joint TB the activity and duration of the specific process [1,2].
    [Show full text]
  • Neurological Impairment in a Patient with Concurrent Cervical Disc Herniation and POEMS Syndrome
    European Spine Journal (2019) 28 (Suppl 2):S51–S55 https://doi.org/10.1007/s00586-019-05914-5 CASE REPORT Neurological impairment in a patient with concurrent cervical disc herniation and POEMS syndrome Tingxian Ling1 · Limin Liu1 · Yueming Song1 · Shilian Zhou1 · Chunguang Zhou1 Received: 24 July 2018 / Revised: 16 December 2018 / Accepted: 9 February 2019 / Published online: 13 February 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose POEMS syndrome is a rare clonal plasma cell disease characterized by polyneuropathy, organomegaly, endocrinopa- thy, M protein, and skin changes. We report a rare case of neurological impairment in patients with concurrent cervical disc herniation and POEMS syndrome. Methods A patient presented to a local hospital with C3/4 and C4/5 disc herniation, apparent spinal cord compression con- comitant with neurological signs, and concurrent POEMS syndrome. Anterior cervical discectomy and fusion was performed. Results The limb numbness was only slightly alleviated, and 10 days postoperatively the patient complained of muscle weak- ness of the extremities and was referred to our hospital. The patients exhibited non-typical neurological signs and an enlarged liver and spleen that could not be explained. Electroneuromyography and immunofxation electrophoresis produced abnormal results. We diagnosed concurrent POEMS syndrome, for which drug therapy was prescribed. The patient’s symptoms receded. Conclusion Patients presenting with cervical spondylopathy and non-typical neurological signs and symptoms or other systemic problems should be evaluated for the presence of concurrent disease and ruled out diferential diagnoses. Keywords Neurological impairment · POMES syndrome · Cervical disc herniation · Cervical spondylosis Introduction a chronic demyelinating autoimmune disease that has symp- toms similar to those associated with myelopathy: spasticity, Cervical disc herniation is a common spinal disorder that sensory disturbances, gait ataxia, weakness.
    [Show full text]
  • ICD-9 to ICD-10 Mapping Tool Courtesy Of: the Paperwork Project
    ICD-9 to ICD-10 Mapping Tool Courtesy of: The Paperwork Project Spinal Subluxation ICD-9 ICD-10 M99.00 Segmental and somatic dysfunction, Head region (occipito-cervical) 739.0 Segmental and somatic dysfunction, Head region (occipito-cervical) M99.10 Subluxation complex (vertebral), Head region M99.01 Segmental and somatic dysfunction, Cervical region 739.1 Segmental and somatic dysfunction, Cervical region M99.11 Subluxation complex (vertebral), Cervical region M99.02 Segmental and somatic dysfunction, Thoracic region 739.2 Segmental and somatic dysfunction, Thoracic region M99.12 Subluxation complex (vertebral), Thoracic region M99.03 Segmental and somatic dysfunction, Lumbar region 739.3 Segmental and somatic dysfunction, Lumbar region M99.13 Subluxation complex (vertebral), Lumbar region M99.04 Segmental and somatic dysfunction, Sacral region 739.4 Segmental and somatic dysfunction, Sacral region M99.14 Subluxation complex (vertebral), Sacral region M99.05 Segmental and somatic dysfunction, Sacroiliac, hip, pubic regions 739.5 Segmental and somatic dysfunction, Sacroiliac, hip, pubic regions M99.15 Subluxation complex (vertebral), Pelvic region 839.08 Closed dislocation, Multiple cervical vertebra (injury) S13.101_ Dislocation of unspecified cervical vertebra (injury) ** 839.20 Closed dislocation, Lumbar vertebra (injury) S33.101_ Dislocation of unspecified lumbar vertebra (injury) ** 839.21 Closed dislocation, Thoracic vertebra (injury) S23.101_ Dislocation of unspecified thoracic vertebra (injury) ** 839.42 Closed dislocation, Sacrum,
    [Show full text]
  • Percutaneous Conchotome Muscle Biopsy. a Useful Diagnostic and Assessment Tool CHRISTINA DORPH, INGER NENNESMO, and INGRID E
    Percutaneous Conchotome Muscle Biopsy. A Useful Diagnostic and Assessment Tool CHRISTINA DORPH, INGER NENNESMO, and INGRID E. LUNDBERG ABSTRACT. Objective. To evaluate the diagnostic yield, performance simplicity, and safety of the percutaneous conchotome muscle biopsy technique for clinical and research purposes in an outpatient rheuma- tology clinic. Methods. Biopsies taken by rheumatologists in an outpatient clinic during 1996 and 1997 were eval- uated for histopathological and clinical diagnoses. Results. A total of 149 biopsies were performed on 122 patients. Physicians learned the method easily. Samples were of adequate size and quality to allow for diagnostics. In total 106 biopsies were taken due to different diagnostic suspicions: 24 polymyositis (PM) or dermatomyositis (DM); 43 PM, DM, or vasculitis in addition to another rheumatic condition; 19 systemic vasculitis; and 20 myalgias. Criteria for definite or probable PM/DM were fulfilled in 21 patients, 18 with positive biopsies. Thirteen patients received vasculitis as clinical diagnosis, 3 with positive biopsies. No patient with myalgia had a biopsy with inflammatory changes. Fifteen of 43 rebiopsies performed to assess disease activity had signs of active inflammation. In 48% there were changes in immuno- suppressive therapy after biopsy results. Four complications occurred; one was a serious subfascial hematoma. Conclusion. The percutaneous conchotome muscle biopsy technique gives a good size sample that allows for diagnostic evaluation and has a high yield in patients with myositis. It is a simple proce- dure, easy to learn and to perform, with a low complication rate and minimum discomfort for the patient. The method can preferably be used as a diagnostic tool and to perform repeated biopsies to assess the effect of a given therapy for both clinical and research purposes.
    [Show full text]
  • IN the UNITED STATES COURT of FEDERAL CLAIMS OFFICE of SPECIAL MASTERS No
    IN THE UNITED STATES COURT OF FEDERAL CLAIMS OFFICE OF SPECIAL MASTERS No. 10-565V Filed: June 11, 2014 For Publication * * * * * * * * * * * * * * * * * * * * * * * * * * * * MEGAN L. GODFREY, * HPV Vaccine; Gardasil; Juvenile * Ankylosing Spondylitis; JAS; Petitioner, * Causation-in-Fact; Expert; v. * Qualifications. * SECRETARY OF HEALTH * AND HUMAN SERVICES, * * Respondent. * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Milton Clay Ragsdale, IV, Ragsdale LLC, Birmingham, AL, for petitioner. Jennifer Reynaud, U.S. Department of Justice, Washington, DC, for respondent. DECISION1 Vowell, Chief Special Master: On August 20, 2010, Megan Godfrey [“petitioner”] filed a petition for compensation under the National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 [the “Vaccine Act” or “Program”]. The petition alleged that the human papillomavirus [“HPV”] and meningococcal conjugate vaccines Ms. Godfrey received on August 22, 2007, caused her to develop juvenile rheumatoid arthritis. Petition at 1-2. 1 Because this decision contains a reasoned explanation for my action in this case, it will be posted on the United States Court of Federal Claims’ website, in accordance with the E-Government Act of 2002, Pub. L. No. 107-347, 116 Stat. 2899, 2913 (Dec. 17, 2002). As provided by Vaccine Rule 18(b), each party has 14 days within which to request redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the entire decision will be available to the public. 2 National Childhood Vaccine Injury Act of 1986, Pub.
    [Show full text]
  • Doctoral Thesis Effectiveness of Tumor Necrosis Factor Inhibitors in Patients
    Bente Glintborg 2018 Glintborg Bente UNIVERSITY OF COPENHAGEN FACULTY OF HEALTH AND MEDICAL SCIENCES Effectiveness of Effectiveness Doctoral thesis Doctoral thesis Bente Glintborg, 2018 Bente Glintborg, 2018 tumor Effectiveness of tumor necrosis factor inhibitors in patients necrosis factor inhibitors in patients with psoriatic arthritis and arthritiswithaxial psoriatic inhibitorsin patients factor necrosis with psoriatic arthritis and axial spondyloarthritis – treatment response, drug retention and predictors thereof Results from the nationwide DANBIO registry Copenhagen Center for Arthritis Research (COPECARE) Center for Rheumatology and Spine Diseases Centre of Head and Orthopaedics Rigshospitalet, Glostrup spondyloarthritis ISBN 978-87-970989-0-5 Doctoral thesis Effectiveness of tumor necrosis factor inhibitors in patients with psoriatic arthritis and axial spondyloarthritis – treatment response, drug retention and predictors thereof Results from the nationwide DANBIO registry Bente Glintborg, MD, PhD 2018 The DANBIO registry and Copenhagen Center for Arthritis Research, COPECARE Center for Rheumatology and Spine Diseases Centre of Head and Orthopedics Rigshospitalet 1 © Bente Glintborg 2018 ISBN 978-87-970989-0-5 All rights reserved. No parts of this publication may be reproduced or transmitted, in any form or by any means, without permission The Faculty of Health and Medical Sciences at the University of Copenhagen has accepted this dissertation, which consists of the already published dissertations listed below, for public defence
    [Show full text]
  • Low Back Pain: a Pathway to Prioritisation
    National Health Committee – Low Back Pain: A Pathway to Prioritisation National Health Committee Low Back Pain: A Pathway to Prioritisation Page 1 National Health Committee – Low Back Pain: A Pathway to Prioritisation National Health Committee (NHC) The National Health Committee (NHC) is an independent statutory body charged with prioritising new and existing health technologies and making recommendations to the Minister of Health. It was reformed in 2011 to establish evaluation systems that would provide the New Zealand people and the health sector with greater value for money invested in health. The NHC Executive is the secretariat that supports the Committee. The NHC Executive’s primary objective is to provide the Committee with sufficient information for it to make decisions regarding prioritisation and reprioritisation of interventions and services. They do this through a range of evidence-based products chosen according to the nature of the decision required and timeframe within which decisions need to be made. The New Zealand Government has asked that all new diagnostic and treatment (non-pharmaceutical) services, and significant expansions of existing services, are to be referred to the NHC. In August 2011 the NHC was appointed with new Terms of Reference and a mandate to establish the capacity to assess new and existing health technologies. Its objectives (under Section 4.2 of its Terms of Reference – www.nhc.health.govt.nz) include contributing to improved value for money and fiscal sustainability in the health and disability sector by: providing timely advice and recommendations about relative cost-effectiveness based on the best available evidence; providing advice and recommendations which influence the behaviour of decision makers including clinicians and other health professionals; providing advice and recommendations which are reflected in resource allocation at national, regional and local levels; and contributing to tangible reductions in the use of ineffective interventions and improved targeting to those most likely to benefit.
    [Show full text]
  • Diagnosis and Treatment of Dermatomyositis-Systemic Lupus
    Diagnosis and Treatment of Dermatomyositis-Systemic Lupus Erythematosus Overlap Syndrome Preston Williams1; Benjamin McKinney, MD2 1Texas A&M College of Medicine; 2Baylor University Medical Center Family Medicine Residency Introduction Case Description Discussion Dermatomyositis is an autoimmune condition classically A punch biopsy of her rash showed atrophic epithelium with This case of overlap syndrome between dermatomyositis and characterized by symmetric proximal muscle weakness, dyskeratotic keratinocytes, vacuolar interface changes, superficial systemic lupus erythematosus presents a rare but important inflammatory muscle changes, and dermatologic abnormalities.1 perivascular and lichenoid inflammation, and pigment challenge to the primary care physician. Our patient presented Several studies have shown that the inflammatory myopathies, incontinence consistent with systemic lupus erythematosus initially with arthralgias and fatigue, symptoms more such as dermatomyositis, commonly overlap with other (SLE). The patient was started on prednisone 40 mg daily for a 2- characteristic of systemic lupus erythematosus. However, these connective tissue disorders, significantly complicating the week taper to 10 mg and hydroxychloroquine 200 mg daily with symptoms were followed by a facial rash that involved the diagnosis.2 The reported incidence of overlap syndrome ranges marked improvement in symptoms. Further lab work-up was nasolabial folds and periorbital regions more in line with from 11% to 40% in patients diagnosed with significant
    [Show full text]
  • Supplemental File Supplemental Table 1: Co-Morbidity Definitions
    Supplemental File Supplemental Table 1: Co-morbidity definitions NCD group UK Biobank self-reported illnesses included Hypertension Hypertension Essential hypertension Chronic cardiac disease Angina Cardiomyopathy Heart attack/myocardial infarction heart failure/pulmonary oedema Hypertrophic cardiomyopathy Coronary angioplasty (ptca) +/- stent Coronary artery bypass grafts Triple heart bypass Chronic respiratory disease Asthma Bronchiectasis Chronic obstructive airways disease/COPD Emphysema Emphysema/chronic bronchitis Fibrosing alveolitis/unspecified alveolitis Interstitial lung disease Other chronic respiratory problems Pulmonary fibrosis Diabetes Diabetes Diabetic eye disease Diabetic nephropathy Diabetic neuropathy/ulcers Type 1 diabetes Type 2 diabetes Cancer Any cancer diagnosis during lifetime Chronic liver disease Liver failure/cirrhosis Non-infective hepatitis Oesophageal varices Primary biliary cirrhosis Chronic kidney disease Diabetic nephropathy Immunoglobulin A (IgA) nephropathy Kidney nephropathy Polycystic kidney Renal failure not requiring dialysis Renal failure requiring dialysis Renal/kidney failure Prior stroke/TIA Brain haemorrhage Ischaemic stroke Stroke Subarachnoid haemorrhage Transient ischaemic attack (TIA) Other neurology disease Cerebral palsy Epilepsy Motor neurone disease Multiple sclerosis Myasthenia gravis Parkinson’s disease Psychiatric disease Depression Mania/bipolar disorder/manic depression Postnatal depression Schizophrenia Chronic inflammatory and Ankylosing spondylitis autoimmune rheumatic disease
    [Show full text]
  • ICD-10 Codes for Trigger Point Injections
    ICD-10 Codes for Trigger Point Injections Code Description Comment G89.0 Central pain syndrome M08.1 Juvenile ankylosing spondylitis M25.70 Osteophyte, unspecified joint M25.721 Osteophyte, right elbow M25.722 Osteophyte, left elbow M25.729 Osteophyte, unspecified elbow M25.731 Osteophyte, right wrist M25.732 Osteophyte, left wrist M25.739 Osteophyte, unspecified wrist M25.741 Osteophyte, right hand M25.742 Osteophyte, left hand M25.749 Osteophyte, unspecified hand M25.751 Osteophyte, right hip M25.752 Osteophyte, left hip M25.759 Osteophyte, unspecified hip M25.761 Osteophyte, right knee M25.762 Osteophyte, left knee M25.769 Osteophyte, unspecified knee M25.771 Osteophyte, right ankle M25.772 Osteophyte, left ankle M25.773 Osteophyte, unspecified ankle M25.774 Osteophyte, right foot M25.775 Osteophyte, left foot M25.776 Osteophyte, unspecified foot M35.3 Polymyalgia rheumatica M41.112 Juvenile idiopathic scoliosis, cervical region M41.113 Juvenile idiopathic scoliosis, cervicothoracic region M41.114 Juvenile idiopathic scoliosis, thoracic region M41.115 Juvenile idiopathic scoliosis, thoracolumbar region M41.116 Juvenile idiopathic scoliosis, lumbar region M41.117 Juvenile idiopathic scoliosis, lumbosacral region M41.119 Juvenile idiopathic scoliosis, site unspecified M41.122 Adolescent idiopathic scoliosis, cervical region M41.123 Adolescent idiopathic scoliosis, cervicothoracic region M41.124 Adolescent idiopathic scoliosis, thoracic region M41.125 Adolescent idiopathic scoliosis, thoracolumbar region M41.126 Adolescent idiopathic
    [Show full text]
  • Ninth International Congress on Spondyloarthritis
    Ninth International Congress on Spondyloarthritis October 23–25, 2014 Gent, Belgium Presidents Martin Rudwaleit Dept. of Internal Medicine and Rheumatology Klinikum Bielefeld Bielefeld, Germany John D. Reveille Division of Rheumatology The University of Texas Health Science Center at Houston Houston, USA Local Organisers Herman Mielants Dirk Elewaut Filip Van den Bosch Dept. of Rheumatology, University of Gent Gent, Belgium Abstracts Page no. Invited Lectures (INV1 – INV25) 766 Oral Presentations (O1 – O12) 771 Short Oral Presentations (SO1 – SO5) 775 Poster Presentations (P1 – P182) 776 Author Index 835 Clinical and Experimental Rheumatology 2014; 32: 765-838. Invited Lectures Ninth International Congress on Spondyloarthritis Invited Lectures (SCORE), which are based on CV risk factors. Statin and/or antihypertensive treatment is then only initiated above a certain threshold, e.g. a 10-year CV mor- tality risk of 10% or more or a 10 year CV morbidity of 20% or more. EULAR recommendations for CV-RM in patients with IJD advised yearly CV INV1 risk screening For RA it is recommended to adapt existing risk functions, such as SCORE, by a multiplier of 1.5 to achieve a more appropriate estimation of THE INTESTINAL MICROBIOME AND THE IMMUNE SYSTEM the 10 years CV risk (9). Obviously, effective suppression on the inflammatory process is necessary to further decrease the CV-risk. For SLE it is recommended Eberl G. the LDL-cholesterol levels should below 2.6 mmol/L and blood pressure levels Lymphoid Tissue Development Unit, Institut Pasteur, Paris, France be lower than 130/80 mmHg. When there are no contraindications, aspirin should be given to patients with a history of CV events (including myocardial infarction, RORγt+ T cells and RORγt+ innate lymphoid cells (ILCs) play central roles in angina or stroke), the presence of antiphospholipid antibodies, hypertension, dia- the development of the immune system, in homeostasis of the host with its sym- betes, hypercholesterolemia, or smoking (10).
    [Show full text]